Wednesday, 20 July 2022 | 10:00 am – 12:00 pm (EDT)
Overview of Non-Medical Switching Practices of Biologicals/Biosimilars in Different Regions and the Importance of Safeguarding the Physician–Patient Relationship
Speakers' Presentations Available
The advent of biologicals offers significant benefits and enhanced quality of life for patients with chronic diseases, such as rheumatoid arthritis, multiple sclerosis and cancer. However, finding a working treatment regimen may take a long time and involves trial and error for a patient’s individual case.
Nevertheless, government policies that force biosimilar switching for non-medical and strictly economic reasons may ultimately affect patients’ treatment and their well-being, create mistrust in the healthcare system, undermine competition, increase total healthcare costs, and act as a barrier to innovation and future access to new biological drugs for patients.
Non-medical switching should consider two governing principles: 1) the physician–patient relationship must be protected to ensure the best outcomes; and 2) patients stabilized on a biological therapy should not be forced to undergo a non-medical switch.
Second ASBM/GaBI Biosimilar Webinar
In this online event, academic clinicians with specialties in oncology and ophthalmology, patient advocates, policymakers and regulatory experts from Canada and the US will share their experience and knowledge on medical switching and principles and guidance on interchangeability of biologicals/biosimilars, highlighting the specific concerns on, and the importance of a multi-stakeholder approach protecting the physician–patient relationship in the practice of non-medical switching of biologicals/biosimilars.
Improved information and protecting the physician–patient relationship in medical switching of biologicals/biosimilars will encourage smooth uptake of biosimilars.
To gain an insight on practice of switching biologicals/biosimilars in Europe and the US
To learn the current state of non-medical switching policies of biologicals/biosimilars in Canada
To hear the physicians’ concerns and experience of non-medical switching of biologicals/biosimilars
To understand the principles and guidance of interchangeability of biologicals/biosimilars in the US
To recognize patients’ concerns in non-medical switching of biologicals/biosimilars
To evaluate the role of healthcare providers (physicians, health policymakers, pharmacists, nurses) and patients in non-medical switching of biologicals/biosimilars
To identify the important elements and educational needs on non-medical switching of biologicals/biosimilars practices
To produce and publish a meeting report in GaBI Journal covering recommendations and informational programmes required on non-medical switching policies of biologicals/biosimilars
NEXT ONLINE EVENT!
ASBM–GaBI Biosimilar Webinar Series
This webinar is the second in a series.
The discussion will continue at the third webinar on ‘Ophthalmic Biosimilars’ in September 2022. More information will be available soon or contact us for more information!
Join the Club
Join our email list and get access to upcoming ASBM-GaBI webinars exclusive to our subscribers